D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Monday, H.C. Wainwright resumed coverage on Curis (NASDAQ:CRIS), a clinical-stage biopharmaceutical company, with a Buy rating and a price target of $17.00. Currently trading at $2.03, with a market capitalization of $21.24 million, Curis has received a strong Buy consensus from analysts, with price targets ranging from $12 to $20. According to InvestingPro data, the stock has shown significant volatility, with a beta of 3.65. The firm’s analysis highlighted Curis’ development of emavusertib, an investigational drug positioned as a potential first-in-class oral inhibitor targeting IRAK4, a protein involved in the progression of certain cancers such as leukemia and lymphoma. While the company’s revenue grew by 14.17% in the last twelve months, InvestingPro analysis indicates weak financial health metrics, with an overall score of 1.69 out of 5.
Emavusertib functions by interrupting the signaling downstream of the toll-like receptor (TLR) superfamily, which is a key player in the activation of NF-kB signaling. This pathway is known for its overactivity, which can lead to the proliferation of B-cells and B-cell lymphoma. The focus on this novel mechanism of action underpins the analyst’s positive outlook for the company’s lead drug candidate.
Curis is at the forefront of cancer treatment innovation with its strategic focus on emavusertib. The company’s efforts are concentrated on targeting IRAK4, which is implicated in the TLR pathway, an area that has not been extensively targeted by existing therapies. This pathway’s role as a primary and independent activator of NF-kB signifies its potential impact on the treatment of B-cell malignancies.
The $17.00 price target set by H.C. Wainwright reflects the firm’s confidence in Curis’ direction and the therapeutic potential of emavusertib. The company’s stock is anticipated to perform well as it continues to progress through clinical trials and towards potential commercialization. Based on InvestingPro’s Fair Value analysis, the stock appears undervalued despite recent challenges, including a -82.8% return over the past year. Discover more insights and 7 additional ProTips about Curis in the comprehensive Pro Research Report, part of the analysis available for 1,400+ US stocks on InvestingPro.
Curis’ journey in developing emavusertib and its potential market impact will be closely watched by investors and industry experts alike. The company’s innovative approach to cancer treatment could bring new hope to patients affected by leukemia, lymphoma, and other related conditions.
In other recent news, Curis Inc. reported a net loss of $10.6 million, or $1.25 per share, for the first quarter of 2025, which is an improvement from the $11.9 million loss, or $2.05 per share, reported in the same quarter last year. The company emphasized advancements in its cancer treatment pipeline, particularly with emavucertib, which showed promising results in ongoing studies. Curis has also announced the appointment of Dr. Ahmed Hamdi as the new Chief Medical (TASE:BLWV) Officer. The company projects its cash runway will extend into the fourth quarter of 2025, providing financial stability for ongoing operations and research. Research and development expenses decreased to $8.5 million from $9.6 million, while general and administrative expenses fell to $4 million from $4.9 million. Curis highlighted that its cash and cash equivalents totaled $20.3 million as of March 31, 2025. The company plans to continue its clinical development efforts and anticipates presenting further data at upcoming conferences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.